TransMedics (Nasdaq:TMDX) announced today that it intends to offer $300 million in convertible senior unsecured notes. Andover, Massachusetts-based TransMedics develops organ transplant technology. It offers FDA-approved lung and heart transplant technology, such as the OCS Heart that received pre-market approval in April 2022. The company’s offering remains subject to market and other conditions. The notes […]
transmedics
TransMedics more than doubles revenue in Q1, raises guidance
TransMedics (Nasdaq:TMDX) shares rose this morning on first-quarter results that beat the consensus forecast. Shares of TMDX ticked up 1.2% at $78.78 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.3%. The Andover, Massachusetts-based organ transplant technology developer posted losses of […]
TransMedics grows sales more than 200% in Q4 results
TransMedics (Nasdaq:TMDX) this week announced fourth-quarter results that beat the overall consensus on Wall Street. The Andover, Massachusetts-based company reported profit losses of $6.7 million, or -21¢ per share, on sales of $31.4 million, for the three months ended Dec. 31, 2022, for a sales growth of 224.52% compared to Q4 2021. NuVasive also reported […]
TransMedics grows sales 151% in Q2
TransMedics (NSDQ:TMDX) this week posted second-quarter financial results that beat the revenue consensus on Wall Street and missed earnings estimates. The Andover, Massachusetts-based organ preservation tech company reported losses of $11.5 million, or -41¢ per share, on sales of $20.5 million for the three months ended June 30, for a bottom-line loss of 8% on sales […]
TransMedics skyrockets on Q1 results, increased 2022 guidance
TransMedics (Nasdaq:TMDX) shares got a massive boost today on first-quarter sales that were 64% higher than the consensus forecast. TMDX shares were up more than 30% at $28.44 apiece by midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down slightly. The Andover, Massachusetts–based […]
FDA approves Transmedics OCS Heart organ transplant system
TransMedics (Nasdaq:TMDX) announced today that it received FDA premarket approval (PMA) for its OCS Heart system. FDA PMA allows Andover, Massachusetts-based TransMedics to expand the pool of eligible heart donors in the U.S. to organs from donors after circulatory death (DCD). The company had previously received PMA for the OCS Heart system for use with […]
TransMedics soars as revenues beat The Street by $2M
TransMedics (NSDQ:TMDX) shares were up more than 27% today after it reported Q4 revenues that beat Wall Street expectations by more than $2 million. Regulatory wins enabled the Andover, Massachusetts–based organ preservation tech company to bring in $9.7 million during the quarter ended Dec. 31, 2021, representing 26.8% sales growth from Q4 2020. Analysts were […]
FDA approves Transmedics’ OCS Liver preservation system
TransMedics (NSDQ:TMDX) today announced that it has received FDA premarket approval for its OCS Liver system for use with organs from donors after brain death and circulatory death. Andover, Massachusetts–based Transmedics designed the device to preserve and monitor the hemodynamics and metabolic function. It allows for ex-vivo assessment of liver allografts from brain dead and circulatory […]
FDA approves TransMedics’ OCS Heart system
TransMedics (NSDQ:TMDX) announced today that it received FDA premarket approval for its OCS Heart system. Andover, Massachusetts-based TransMedics designed its OCS Heart system for use with organs from donors after brain death with indication for preserving donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of prolonged cold static cardioplegic […]
FDA clears TransMedics OCS Lung System
TransMedics (NSDQ:TMDX) has won FDA clearance of its OCS Lung System to provide hypothermic flushing, storage and transportation of donor lungs for transplantation. “This FDA clearance marks another achievement for TransMedics as we assemble the most comprehensive, market-leading portfolio of organ preservation products to meet the clinical needs of the organ transplant market,” TransMedics CEO […]
FDA advisory panel gives positive ruling on TransMedics OCS Liver System
TransMedics (NSDQ:TMDX) announced last night that an FDA advisory panel issued a favorable vote supporting approval for its OCS Liver System. Yesterday, the Nasdaq market halted trading of TransMedics’ common stock as it awaited the outcome of a meeting of the FDA’s Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee, set to review […]
